Acrivon Therapeutics to Present Phase 1 Data on ACR-2316 Cancer Drug at EORTC-NCI-AACR Symposium

PUBT · 14h ago
Acrivon Therapeutics to Present Phase 1 Data on ACR-2316 Cancer Drug at EORTC-NCI-AACR Symposium
  • Acrivon Therapeutics will present Phase 1 results for cancer drug ACR-2316 on November 20, 2026, at EORTC-NCI-AACR in Barcelona.
  • The presentation will cover safety, dose optimization and preliminary antitumor activity from the dose-escalation study.
  • A November 19 poster will highlight research showing greater activity for ACR-2316 than clinical-stage WRN helicase inhibitors.
  • A November 20 poster will describe oral CDK11 inhibitors that induced complete tumor regression in acute myeloid leukemia models.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041630PRIMZONEFULLFEED9870567) on November 04, 2026, and is solely responsible for the information contained therein.